Buccal drug delivery systems have been attracting much attention as drug formulations intended for anti-inflammatory and analgesic therapies in the oral cavity. These formulations are expected to increase therapeutic effects and reduce systemic adverse reactions by concentrating the drug in the target tissue. One particular problem associated with the treatment of oral cavity diseases is short duration of therapeutic efficacy due to rapid dilution and washout from the oral cavity by saliva.
together with addition of 5 w/v% HPC or PVA. One hundred and twenty-five microliters of the aqueous solution was placed on a Teflon cell (0.79 cm 2 ) and put in a desiccator with silica gel at room temperature overnight. Additional 125 ml drug solution was overlaid to the film and dried in the desiccator with silica gel at room temperature completely. The reason why two-step drying was conducted was to minimize the formation of the film edge.
Dissolution Test In vitro release of drugs was tested using a modified JP XIV dissolution apparatus. The film dosage form prepared according to the above-mentioned method was attached to the rotatory shaft with an adhesive tape. The shaft was rotated at 50 rpm in 50 ml of artificial saliva in a 50 ml glass beaker thermostated at 37°C. The artificial saliva was composed of 14.4 mM NaCl, 16.1 mM KCl, 1.31 mM CaCl 2 · 2H 2 O, 0.545 mM MgCl 2 · 6H 2 O, and 1.96 mM K 2 HPO 4 , and the pH was adjusted to 5.7 with HCl. Two hundred and fifty microliters were taken at 1, 3, 5, 7, 10, 15, 20, 30, 45, 60, 90 , and 120 min and subjected to further analysis. To keep the volume of dissolution medium constant, an equivalent volume of fresh artificial saliva was added after sampling.
Determination of Lidocaine The lidocaine concentrations in the samples obtained from dissolution test were determined using an HPLC system (LC-6A, Shimadzu, Kyoto). A mobile phase composed of water, methanol, and phosphoric acid (79 : 20 : 1) was flowed through an Inersil ODS-2 column (5 mm, 4.6ϫ150 mm, Nacalai Tesque Inc., Tokyo) at the rate of 1.2 ml/min at 36°C. The detection wavelength for lidocaine was 220 nm.
Determination of Ketoprofen The ketoprofen concentrations in the samples obtained from dissolution test were determined using an HPLC system (LC-10Avp, Shimadzu, Kyoto). A mobile phase composed of 0.06 M KH 2 PO 4 , acetonitrile, and triethylamine (65 : 35 : 0.1) was flowed through an Inersil ODS-2 column (5 mm, 4.6ϫ150 mm, Nacalai Tesque Inc., Tokyo) at the rate of 1.0 ml/min. The detection wavelength for ketoprofen was 275 nm.
Differential Scanning Calorimetry (DSC) Analysis DSC thermograms of pure drugs, film dosage forms containing drug and b-CyD polymer, and the control films containing drug alone were recorded by DSC system (DSC3200, Mac Science Co,. Tokyo, Japan). All samples containing 1 mg drug were placed in aluminium pans and heated lineally at a scanning rate of 10°C/min from ambient temperature to 200°C. Aluminium oxide was used to calibrate the apparatus.
Competitive Inclusion Complexation Assay TNS (20 mM) and b-CyD polymer (b-CyD unit concentration of 200 mM) were dissolved in pH 7.4 phosphate buffered saline (PBS). One milliliter of the mixture and 5 ml of varying drug concentrations in PBS were mixed and adjusted to 10 ml. The final concentrations of TNS and b-CyD units of the polymer were 2 mM and 20 mM, respectively. After the mixture was incubated at 25°C for 60 min, the fluorescence intensity associated was determined by spectrofluorophotometer (RF-540, Shimadzu, Kyoto), where the excitation and emission wavelengths were 324 and 437 nm, respectively.
Binding Experiment Four hundred milligrams per milliliter lidocaine or 40 mg/ml ketoprofen was incubated with varying amounts of b-CyD polymer in the artificial saliva at 25°C. Approximately 2 ml aliquot of the incubation medium was subjected to ultra-filtration with a polyethersulfone membrane filter (Vivaspin 2 (5000 MWCO), Vivascience AG, Goettingen, Germany). Five hundred microliters aliquot of the filtrate was taken and diluted by 10 times. The drug concentration in the diluted filtrate was determined by the HPLC method. Assuming that the drug and b-CyD untis of the polymer form a 1 : 1 complex and that the concentration of complex was negligible as compared to the concentration of b-CyD, the association constant (K) was calculated using the following equation: (1) where [Drug] total , [Drug] free , and [b-CyD] total were concentrations of free drug, total drug, and total b-CyD, respectively. The K values and their computer-calcualated standard errors were estimated by linear regression method.
RESULTS

Dissolution of Lidocaine and Ketoprofen from Film Dosage Forms
Lidocaine film dosage forms were prepared, using HPC or PVA as a film base. Figure 2 shows the dissolution profiles of lidocaine from the films. When HPC was used as a film base, more than 80% of applied lidocaine was released within 15 min. When b-CyD polymer was added to the film, it took approximately 30 min to release 80% of applied lidocaine. Similar retardation of lidocaine release associated with addition of b-CyD polymer was observed with the PVA base, although the lidocaine release tended to be slower for PVA as compared with HPC. Initial dissolution rates were calculated from the linear portion in early time phase (Table 1) . Addition of b-CyD polymer reduced an initial dissolution rate by 40% for both HPC and PVA bases.
Film dosage forms of ketoprofen were also prepared using HPC as a film base. Figure 3 shows the dissolution profiles of ketoprofen from the films. As compared to lidocaine, the release rate of ketoprofen was slower, where it took more than 75 min for 80% of the amount to be released. When b-
CyD polymer was added to the film, the release rate of ketoprofen was increased, in contrast to the case of lidocaine. The initial dissolution rate was increased by 1.4-folds by addition of b-CyD polymer in the polymer film (Table 2) . Figure 4 shows the DSC thermograms of pure lidocaine or ketoprofen, the HPC film, and the HPC/bCyD polymer film. In the case of lidocaine, a small melting peak of lidocaine was observed at 68-69°C for HPC and HPC/b-CyD polymer film. The endothermic peak for HPC/b-CyD polymer film was slightly larger than that for the HPC film, indicating that crystallinity of lidocaine would be slightly increased by the addition of b-CyD polymer.
DSC Analysis of Lidocaine and Ketoprofen Film Dosage Forms
In contrast, the film dosage forms of ketoprofen did not exhibit any endothermic peak irrespectively of the addition of b-CyD polymer film. Thus, it was indicated that ketoprofen be in the amorphous state in the polymer films.
Confirmation of Drug-b b-CyD Polymer Complexation by Ultrafiltration Method
To confirm the interaction of drugs with b-CyD polymer, we performed binding experiments using ultra-filtration method. Figure 6 shows the relationship between free drug concentration and the concentration of b-CyD polymer. The concentration of free drug molecules in the artificial saliva decreased significantly in a bCyD polymer concentration-dependent manner, while the effect of b-CyD polymer was much more significant with ketoprofen. The association constants calculated assuming that the b-CyD forms 1 : 1 complex with the guest molecule were 6.9Ϯ0.6 and 520Ϯ90 M Ϫ1 for lidocaine and ketoprofen, respectively. Here, it should be noted that the association constant was estimated with the concentration of b-CyD monomer units.
Detection of Lidocaine-b b-CyD Polymer Inclusion Com- plexes Using a Fluorescent Probe As one of convenient methods to investigate formation of inclusion complex, competitive experiments using a fluorescent probe such as TNS have been proposed. 9, 10) The fluorescence associated with TNS increases markedly in a non-polar environment. When TNS forms an inclusion complex with b-CyD, the compound emits strong fluorescence due to hydrophobic environment in the cavity of b-CyD and restricted molecular motion. By using the fluorescent probe, we investigated whether or not lidocaine forms an inclusion complex with b-CyD polymer (Fig. 5) . When TNS was incubated with b-CyD polymer, strong fluorescence was observed as reported with monomeric b-CyD.
Ketoprofen significantly reduced fluorescence associated with TNS-b-CyD polymer complex in a concentration-dependent manner, where relative fluorescence was decreased up to approximately 2% when 20 times higher concentration of ketoprofen than that of b-CyD unit of the polymer was added. Competitive inhibition effect of ketoprofen was comparable to that of progesterone 11) known to be strongly associated with b-CyD. In contrast, no effect of lidocaine was observed even when its concentration was increased up to 1 mM, being 50 times as high as that of b-CyD unit.
DISCUSSION
In the present study, b-CyD polymer retarded the release of lidocaine from mucoadhesive polymer films. Miyoshi et al. 12) reported that b-CyD forms an inclusion complex with lidocaine and improves solubility and stability of the drug. Dollo et al. 13) revealed in their NMR studies that significant changes of chemical shifts assigned to inner protons of bCyD (H3 and H5), as well as proton near the cavity (H6 on the rim of the torus), due to the addition of lidocaine were observed whereas no appreciable shifts detected for protons located outside the cavity of b-CyD. Taking together with the results of DSC and infrared spectroscopy analyses, they concluded that lidocaine molecule may interact with the cavity of b-CyD.
13) Although lidocaine was not associated with bCyD polymer as strongly as to inhibit the formation of TNSb-CyD complex (Fig. 6 ), free concentration of the drug was significantly decreased in b-CyD polymer-concentration dependent manner (Fig. 5) . Therefore, it is likely that decreased thermodynamic activity by complex formation might be one of the reasons why b-CyD polymer retarded the release of lidocaine from the film dosage form. Based on the relationship between b-CyD polymer concentration and free concentration of lidocaine, the association constant for lidocaine-bCyD polymer complex was estimated to be 6.9Ϯ0.6 M
Ϫ1
. Taking into account that the association constant for binding of progesterone and quercetin with monomeric b-CyD was 5000 11) and 130 14) M
, respectively, it was indicated that the binding between lidocaine and b-CyD polymer was very weak.
The endothermic peak for HPC/b-CyD polymer film was slightly larger than that for the HPC film, indicating that crystallinity of lidocaine would be increased by the addition of b-CyD polymer. Since the amount of b-CyD polymer was almost a half of HPC in the film dosage form, it is not surprising that the structure of polymer network might be different between b-CyD polymer-containing film and the control.
Thus, crystallinity of lidocaine in the films might be changed by the addition of b-CyD polymer. It cannot be ruled out that such effect might alter the release rate from the film dosage forms.
Since ketoprofen has a much larger association constant with b-CyD polymer than lidocaine, it was likely that retardation of drug release by b-CyD polymer be more significant with ketoprofen. Nevertheless, the release of ketoprofen from mucoadhesive polymer films was rather increased by addition of b-CyD polymer. There have also been controversial reports regarding the effect of b-CyD on dissolution of drugs in tablet formulations. [15] [16] [17] [18] [19] Horiuchi et al. 15) demonstrated that dissolution rate of diltiazem from the tablets was decreased by the addition of diethylated and triethylated bCyD. In addition, ethylated b-CyD was reported to retard in vitro release of buserelin acetate from oily suspensions. 16) On the contrary, increased dissolution by inclusion complexation with b-CyD or its derivatives has been observed for nifedipine, 17) naproxen, 18) and famotidine. 19) Enhanced dissolution by b-CyD tends to be observed with water-insoluble drugs, presumably since dissolution of water-insoluble drugs in the crystal form would be slower than that from inclusion complexes. Although ketoprofen was in the amorphous state in the polymer films, recrystallization would occur easily after contacting with aqueous solution. When an inclusion complex with b-CyD polymer was being formed, however, the phase transition to water-insoluble crystal forms would not occur. Hence, the release rate of ketoprofen from b-CyD polymer-containing film dosage forms would be higher than that from the control film.
In conclusion, effect of low-molecular-weight b-CyD polymer to the drug release rate from film dosage forms appears to vary according to the strength of interaction with and the solubility of active ingredient. However, this study clearly demonstrated that addition of low-molecular-weight b-CyD polymer to film dosage forms could control in vitro dissolution rate of the drug.
